



DIPLOMA PLC

**VERY STRONG RESULTS.
GREAT MOMENTUM.**

FULL YEAR RESULTS FOR THE YEAR ENDED
30 SEPTEMBER 2025


18 NOVEMBER 2025

AGENDA

OVERVIEW	01
----------	----

FINANCIAL PERFORMANCE	02
-----------------------	----

STRATEGY AND BUSINESS REVIEW	03
---------------------------------	----






OVERVIEW

01

DIPLOMA PLC

VERY STRONG RESULTS, AHEAD OF EXPECTATIONS. GREAT MOMENTUM




¹ Return on Adjusted Trading Capital Employed (ROATCE)

² Including two in FY26


A LONG TRACK RECORD OF COMPOUNDING

ACCELERATED UNDER CURRENT STRATEGY



We're just getting started

DELIVERING SUSTAINABLE QUALITY COMPOUNDING



PEOPLE AND CULTURE

A powerful, thriving
decentralised
culture



Developing
the next
generation
of leaders



Energetic mood



Highly engaged
colleagues



A close-up, low-angle shot of a white wind turbine's nacelle and three blades against a sunset sky. The sky transitions from a deep blue at the top to a warm orange and yellow near the horizon. The water below is dark and calm. The turbine's blades are illuminated by the low sun, creating a strong orange glow. A white crosshair graphic is visible in the upper right quadrant of the image.

FINANCIAL PERFORMANCE

02

DIPLOMA PLC

STRONG FULL YEAR PERFORMANCE

AMBITION...

	FY25	FY24
Organic revenue growth	11%	6%
Revenue growth	12%	14%
Adjusted operating profit margin	22.5%	20.9%
Adjusted EPS growth	21%	21%


...WITH DISCIPLINE

	FY25	FY24
Free cash flow conversion	105%	101%
Return on capital ¹	20.9%	19.1%
Leverage ²	0.8x	1.3x
Dividend growth	5%	5%

Sustainable quality compounding

REVENUE GROWTH


Year ended 30 September



Very strong organic growth

MARGIN EXPANSION


Year ended 30 September



160bps operating margin expansion

COMPOUNDING EPS GROWTH

Year ended 30 September



Continuing our long-term track record

DISCIPLINED STEWARDSHIP OF CAPITAL

CAPITAL ALLOCATION PRIORITIES

1

SELECTIVE INVESTMENT FOR ORGANIC GROWTH

Capital-light model
(c.2% capex / revenue)
drives 90% cash
conversion

2

TARGETED ACQUISITIONS TO DRIVE FUTURE ORGANIC GROWTH

Acquisitions deliver
20% return on capital¹
over time

3

RETURNS TO SHAREHOLDERS

Progressive dividend –
5% annual growth

4


BALANCE SHEET PRUDENCE

Net debt / EBITDA
< 2.0x

Return on capital

STRONG CASH CONVERSION

Year ended 30 September



105% free cash flow conversion

FINANCIAL FIREPOWER


Strong capacity for self-funded growth

Significant leverage headroom

- 0.8x in FY25
- Balance sheet naturally de-levers at 0.4x per annum

Increasing capacity to keep pace with 2x leverage in line with our growth

Funding (£m)



ACQUISITION MOMENTUM

Q4

Haagensen
International Seals
Denmark

Electramed
Life Sciences
Ireland

Spring Solutions¹
International Controls
UK

Alpha Laboratories
Life Sciences
UK

Astro Industries
International Controls
US

WDS Components¹
International Controls
UK

6
bolt-on acquisitions²

£92m
invested

c.8x
EBIT average multiple³

Building quality in our portfolio


DISCIPLINED RETURNS

High returns represents the discipline of compounding

High teens returns is our sweet spot

Acquisitions must reach 20%

FY25 reflects strong performance and lower-than-typical acquisition spend



FY26 GUIDANCE

Organic revenue growth

+6%



Significantly H1 weighted FY26
reflecting strong H2 comparators


Current acquisitions net of
disposals to **reported growth**

+2%

Operating margin

c.22.5%

All at constant currency



Continuing compounding outcomes

OUR FINANCIAL MODEL

AMBITION...

Organic revenue growth
is our first priority

5%

Total revenue growth accelerated
by quality acquisitions*

10%

Value-add drives **strong
operating margins**

20%+

Compounding **EPS growth**

Double
digit

...WITH DISCIPLINE

Capital-light business model
drives **strong cash conversion**

90%

Capital stewardship focused
on **strong returns**

High
teens

Balance sheet discipline
maintains **prudent leverage**

<2.0x

Return to shareholders with
a **progressive dividend**

5%

Sustainable quality compounding

A woman with dark hair tied back, wearing a white lab coat and clear safety glasses, is focused on her work in a laboratory. She is holding a pipette and appears to be transferring liquid into small vials. The background is slightly blurred, showing laboratory equipment and shelves.

STRATEGY AND BUSINESS REVIEW

03

A CLEAR STRATEGY FOR GROWTH

GROW

Organic growth in 3 buckets:

01

END MARKET
EXPOSURE

02

GEOGRAPHIC
EXPANSION

03

PRODUCT
EXTENSION

Complementary acquisitions to drive future organic growth

SCALE


Value-add business model at scale

Powerful decentralised Group at scale

Deliver value responsibly

ATTRACTIVE GROWTH MARKETS

SOME EXAMPLES....



Supporting long-term structural growth

SIGNIFICANT “WHITE SPACE”

			US	CANADA	UK&I	GERMANY	FRANCE	SPAIN	OTHER EU	ANZ			
CURRENT ADDRESSABLE MARKET	CONTROLS	Wire & cable											
		Interconnect											
		Specialty fasteners											
		Specialty adhesives											
		Industrial automation											
	SEALS	Seals											
		Gaskets											
		Hoses & fittings											
		Pumps & valves											
	LIFE SCIENCES	IVD											
		Medtech											
		Scientific											
GROWING ADDRESSABLE MARKET		New product verticals		Market share		Significant		Moderate		Small		White space	

TARGETED ACQUISITIONS ACCELERATE GROWTH

STRONG TRACK RECORD

48
Acquisitions

£1.4bn
Invested

+20%
Return on capital

FY19 - present

HEALTHY ACQUISITION PIPELINE

Long term
pipeline

>4,000

Active
opportunities

>50

Average size
by enterprise value

c.£25m


Well diversified
(by number of opportunities)

By sector




- Seals
- Controls
- Life Sciences

By geography



- N. America
- UK & Ireland
- Europe
- Australia

A BUYER OF CHOICE




CONTROLS: EXCELLENT PERFORMANCE

PERCENTAGE OF GROUP REVENUE*

55%

SECTOR REVENUE MIX



ATTRACTIVE GROWTH MARKETS:

- ✓ Datacentres
- ✓ Aerospace
- ✓ Energy storage
- ✓ Defence

* Pro forma revenue adjusted for acquisitions and disposals completed during the period

	FY25	FY24	Change
Revenue	£836.4m	£652.4m	+28%
Organic growth	+20%	+10%	
Adjusted operating profit	£250.6m	£169.9m	+47%
Adjusted operating margin	30.0%	26.0%	+400bps

FY25 HIGHLIGHTS

- **Windy City Wire:** Double-digit growth. Growing exposure to datacentres
- **International Controls:** Double-digit growth. Attractive market exposure
- **Exceptional Peerless** performance
- **Four** acquisitions – increasing aerospace & defence exposure
- **Positive** outlook

PEERLESS: EXCEPTIONAL PERFORMANCE

+ ATTRACTIVE MARKET
DYNAMICS

+ STRONG MODEL AND
EXCELLENT LEADERSHIP

+ POSITIVE OUTLOOK
AND ATTRACTIVE
LONG TERM PROSPECTS




Exceptional year. Positive outlook

SEALS: SEQUENTIAL IMPROVEMENT

PERCENTAGE OF GROUP REVENUE*



SECTOR REVENUE MIX



ATTRACTIVE GROWTH MARKETS:

- ✓ Water treatment
- ✓ Nuclear
- ✓ Clean energy
- ✓ Infrastructure

* Pro forma revenues adjusted for acquisitions and disposals completed during the period

	FY25	FY24	Change
Revenue	£456.0m	£489.1m	(7%)
Organic growth	+2%	+1%	
Adjusted operating profit	£88.1m	£90.7m	(3%)
Adjusted operating margin	19.3%	18.5%	+80bps

FY25 HIGHLIGHTS


- **Sequential improvement** in H2
- **North America:** Strong recovery in H2
- **International:** Europe recovered well. UK remains tough
- **Investment in talent** – well positioned
- **Portfolio discipline** – small disposals impacted reported performance
- **Positive** outlook

LIFE SCIENCES: MARKET OUTPERFORMANCE

PERCENTAGE OF GROUP REVENUE*

16%


SECTOR REVENUE MIX



43%
Europe inc. UK

39%
North America

18%
Australasia



54%
Medtech

42%
IVD

4%
Scientific and other

ATTRACTIVE GROWTH MARKETS:

✓ In Vitro Diagnostics

✓ Scientific

* Pro forma revenues adjusted for acquisitions and disposals completed during the period

	FY25	FY24	Change
Revenue	£232.1m	£221.9m	+5%
Organic growth	+6%	+6%	
Adjusted operating profit	£45.3m	£46.8m	(3%)
Adjusted operating margin	19.5%	21.1%	(160bps)

FY25 HIGHLIGHTS

- **Strong growth** in Canada, Australia and New Zealand
- **Improving** product portfolio in Europe
- **Two** acquisitions
- **Positive** outlook in challenging healthcare market

DELIVERING SUSTAINABLE QUALITY COMPOUNDING

VERY
STRONG
PERFORMANCE

AMBITION
WITH
DISCIPLINE

STRONG
PORTFOLIO IN
ATTRACTIVE
MARKETS

COMPOUNDING
ACQUISITIONS

POSITIVE
MOMENTUM
INTO FY26

We're just getting started



DIPLOMA PLC

APPENDIX

04

CONSISTENT STRONG PERFORMANCE

Seven-year trends

	7yr average	FY25	FY24	FY23	FY22	FY21	FY20	FY19
Reported revenue growth	+18% ¹	+12%	+14%	+19%	+29%	+46%	(1%)	+12%
Organic revenue growth	+7%	+11%	+6%	+8%	+15%	+12%	(7%)	+5%
Adjusted operating margin	19.3%	22.5%	20.9%	19.7%	18.9%	18.9%	16.2%	17.8%
Adjusted EPS growth	+18% ¹	+21%	+15%	+18%	+26%	+51%	(12%)	+14%
Free cash conversion	99%	105%	101%	100%	90%	103%	113%	78%
Return on capital ²	19.3%	20.9%	19.1%	18.1%	17.3%	17.4%	19.1%	22.9%
Leverage ratio ³	0.8x	0.8x	1.3x	0.9x	1.4x	1.1x	0x	0.1x
Dividend growth	14%	5%	5%	5%	26%	42%	3%	14%

INCOME STATEMENT

Year ended 30 September

£m	FY 25	FY 24	Change
Revenue	1,524.5	1,363.4	+12%
Adjusted operating profit	342.7	285.0	+20%
Operating margin (%)	22.5%	20.9%	
Financial expense, net	(27.3)	(27.0)	
Profit before tax	315.4	258.0	+22%
Effective tax rate	25%	24%	
Minority interests	(0.6)	(0.7)	
Adjusted earnings	236.0	195.4	+21%
Weighted average no. shares (m)	134.1	134.0	
Adjusted earnings per share	176.0p	145.8p	+21%
Total dividend per share	62.3p	59.3p	+5%

SECTOR REVENUE AND PROFIT

	Revenue		
	FY 25 £m	FY 24 £m	Change
Controls	836.4	652.4	+28%
Seals	456.0	489.1	-7%
Life Sciences	232.1	221.9	+5%
Group	1,524.5	1,363.4	+12%

	Organic growth	
	FY 25 %	FY 24 %
	+20	+10
	+2	+1
	+6	+6
	+11	+6

	Adjusted operating profit		
	FY 25 £m	FY 24 £m	Change
Controls	250.6	169.9	+47%
Seals	88.1	90.7	-3%
Life Sciences	45.3	46.8	-3%
Central costs	(41.3)	(22.4)	-84%
Group	342.7	285.0	+20%

	Adjusted operating margin		
	FY 25 %	FY 24 %	Change
	30.0	26.0	+400bps
	19.3	18.5	+80bps
	19.5	21.1	-160bps
	-	-	-
	22.5	20.9	+160bps

BALANCE SHEET

£m, as at 30 September

	FY25	FY24
Goodwill and acquisition intangible assets	1,042.6	1,048.9
Tangible, other intangible, and other financial assets	71.2	66.0
Net lease liabilities	(7.7)	(6.4)
Net working capital	245.7	276.5
Trading capital employed	1,351.8	1,385.0
ROATCE	20.9%	19.1%
Retirement benefit assets, net	1.7	1.5
Acquisition liabilities and assets, net	(24.7)	(23.6)
Net debt	(299.4)	(419.6)
Minority interests and deferred tax, net	(39.7)	(55.3)
Total shareholders' funds (excluding minority interests)	989.7	888.0

DELIVERING VALUE RESPONSIBLY

DELIVERING FOR THE ENVIRONMENT

CLIMATE ACTION

Scope 1 & 2
emission intensity
(tCO₂e/ £1mill)

FY21	NA
FY22	7.6
FY23	7.6
FY24	5.7
FY25	3.1

WASTE REDUCTION

Waste sent
to landfill

FY21	NA
FY22	60%
FY23	32%
FY24	23%
FY25	18%

DELIVERING FOR OUR PEOPLE

DIVERSITY, EQUITY & INCLUSION

Women in senior
management
team

FY21	24%
FY22	27%
FY23	28%
FY24	30%
FY25	32%

COLLEAGUE ENGAGEMENT

Employee Survey
scores

FY21	79%
FY22	79%
FY23	80%
FY24	79%
FY25	78%

DOING BUSINESS RESPONSIBLY

SUPPLY CHAIN

Key suppliers
aligned to our
supplier code

FY21	NA
FY22	59%
FY23	73%
FY24	90%
FY25	89%

HEALTH & SAFETY

Lost time incident
frequency rate

FY21	NA
FY22	3.4
FY23	3.0
FY24	3.6
FY25	2.9